Stocktoria
Autolus Therapeutics plc AUTL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-06-22
Autolus Therapeutics plc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -358.9% | -2385.6% | -10583.1% | — | — |
| Net margin | -381.4% | -2180.5% | -12272.3% | — | — |
| FCF margin | -401.4% | -2256.4% | -9221.0% | — | — |
| Return on assets | -48.8% | -28.2% | -55.5% | -30.4% | -35.0% |
| Return on equity | -161.4% | -51.6% | -186.9% | -49.8% | -45.4% |
| Current ratio | 5.94 | 10.88 | 6.15 | 9.18 | 12.15 |
| Revenue growth | 644.9% | 496.0% | — | — | — |
Source: SEC EDGAR filings · CIK 0001730463 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.